The collaboration will utilize Priaxon’s small molecule drug discovery knowledge in chemistry and technology that is especially suitable for investigating the modulation of PPIs and GSK’s resources and capabilities.
Agreement followed by a successful pilot project, aims at identifying the potential candidates and advancing them into pre-clinical development.
Priaxon CEO Dr. Juergen Kolb said the company uses the strength of its drug discovery platform Priaxplore to develop new small molecule modulators for hard-to-drug PPI targets.
"Our collaboration with GSK and its experts provides the resources and the capabilities to drive these programs forward," Dr. Kolb added.
Financial details in addition to therapeutic areas of the alliance were not revealed.
PPIs play a significant role in several cell signaling pathways and cell-surface receptor-ligand interactions that become dysregulated in disease states.